Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5401_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Contents
- •1.1 Introduction
- •1.2 The Evolution of Herbal Medicine: A Historical Perspective
- •1.3 Diversity of Herbal Pharmacopoeias Across the Globe
- •1.3.1 The Indian Pharmacopoeia (IP)
- •1.3.2 The European Pharmacopoeia (Ph. Eur.)
- •1.3.3 United States Pharmacopoeia (USP)
- •1.3.4 The Russian Federation’s State Pharmacopoeia (SPRF)
- •1.3.6 Hausa Herbal Pharmacopoeia
- •1.5 Ayurveda and the Integration of Nanotechnology
- •1.6 Enhancing Herbal Medicines Through Nanotechnology
- •1.7 Approaches of Nanotechnology in Herbal Medicine
- •1.7.1 Solid Lipid Nanoparticles (SLN)
- •1.7.2 Nanoemulsions
- •1.7.3 Liposomes
- •1.7.4 Ethosomes, Transferosomes, and Transethosomes
- •1.7.5 Niosomes and Phytosomes
- •1.7.6 Micelles, Dendrimers, and Nanostructured Lipid Carriers (NLCs)
- •1.7.7 Nanoparticles, Nanocapsules, and Nanogels
- •1.8 Types of Novel Drug Delivery Systems (NDDS)
- •1.9 Nanotechnology and Its Applications
- •1.10 Efficacy and Safety of Herbal Medicine
- •1.11 Concept of Bhasma and Nanotechnology
- •1.11.1 Nanoparticle Nature of Bhasma
- •1.3.5 Romanian Pharmacopoeia (RPh)
- •1.12 Supermolecules and Nanotechnology
- •1.14 Future Prospects of Nanomedicines
- •1.15 Conclusion
- •References
- •2.1 Introduction
- •2.2 Prehistory
- •2.2.1 Ancient Civilization
- •2.2.1.1 Mesopotamia
- •2.2.1.2 Ancient Egypt
- •2.2.1.3 India, China, Greece, & Rome
- •2.2.1.3.1 India
- •2.2.1.3.2 China
- •2.2.1.3.3 Greece and Rome
- •2.3 Middle Ages and Beyond
- •2.3.1 Translation of Herbals
- •2.3.2 Early Modern Era
- •2.4 Modern Times
- •2.5 Current Status
- •2.6 Challenges Associated
- •2.6.1 Regulation and Safety of Herbal Medications
- •2.6.2 Quality Control of Herbal Medicine
- •2.6.3 Safety Monitoring of Herbal Medicines
- •2.6.4 Bioavailability of Herbal Medicines
- •2.6.5 Clinical Trials
- •2.7 Future Perspectives
- •2.8 Conclusion
- •References
- •3.1 Introduction
- •3.2 Herbal Extraction
- •3.2.2 Choice: Solvent Selection of a Suitable Medium
- •3.3 Supercritical Fluid Extraction (SFE)
- •3.3.1 Working Principle of SFE
- •3.3.2 Parts of the SFE System
- •3.3.3 Process of extraction
- •3.3.4 Applications
- •3.4 Microwave-Assisted Extraction (MAE)
- •3.4.1 Working Principle
- •3.4.2 Components of a Microwave-Assisted Extraction System
- •3.4.3 Method of Extraction from Herbs by MAE
- •3.5 Ultrasound-Assisted Extraction (UAE)
- •3.5.1 Working Principle
- •3.9.3 Applications of GC-MS in Herbal Analysis
- •3.9.4 Endowed Oil Analysis
- •3.9.5 Alkaloids and Phenolic Compounds
- •3.9.6 Terpenoids
- •3.9.7 Quantitative Analysis
- •3.9.8 Data Analysis and Interpretation
- •3.10 Liquid Chromatography-Mass Spectrometry (LC-MS)
- •3.10.1 Principles of Liquid Chromatography-Mass Spectrometry
- •3.5.1.1 Cell Disruption
- •3.5.1.2 Increased Mass Transport
- •3.5.1.3 Enhanced Solvent Effectiveness
- •3.5.2 Parts of the Ultrasound-Assisted Extraction System
- •3.5.3 Method of Extraction from Herbs
- •3.6 Pressurized Liquid Extraction (PLE)
- •3.6.1 Definition
- •3.6.2 Working Principle
- •3.6.3 Parts of the PLE System
- •3.6.4 PLE Extraction Method
- •3.7 Subcritical Water Extraction (SWE)
- •3.7.1 Supercritical fluids
- •3.7.2 Supercritical Fluid Extraction (SFE)
- •3.7.3 Working Principle of Subcritical Water Extraction (SWE)
- •3.7.4 Parts of the Subcritical Water Extraction System
- •3.7.5 Process of Subcritical Water Extraction
- •3.8 High-Performance Liquid Chromatography (HPLC)
- •3.8.1 Principles of HPLC
- •3.8.2 Bioactive Compounds Analysis
- •3.8.2.1 Phenolic Compounds
- •3.8.2.2 Alkaloids
- •3.8.2.3 Terpenoids
- •3.8.3 Recent Advances in HPLC Techniques
- •3.8.3.1 Ultra-High-Performance Liquid Chromatography
- •3.8.3.2 HPLC-MS
- •3.8.3.3 Chiral HPLC
- •3.8.4 Applications of Herbal Medicine
- •3.8.4.1 Quality Control
- •3.8.4.2 Pharmacokinetic
- •3.8.4.3 Challenges and Prospects for Further Study
- •3.9 Gas Chromatography-Mass Spectrometry (GC-MS)
- •3.9.1 Principles of GC-MS
- •3.9.2 Sample Preparation
- •3.10.2 Methods for LC-MS Detection Analysis
- •3.10.2.1 Applications of LC-MS in Herbal Analysis
- •3.10.3 Principles of FTIR
- •3.10.4 Application of FTIR in Herb Analysis
- •3.10.5 Phytochemical Identification
- •3.10.6 Quantitation of Bioactive Compounds
- •3.10.7 Structural Elucidation
- •3.10.8 Sample Preparation for FTIR Analysis
- •3.10.9 Direct Analysis
- •3.10.10 Extraction
- •3.10.11 Pellet Preparation
- •3.10.12 Thin Films
- •3.10.13 Data Analysis and Interpretation
- •3.10.14 Advantages of FTIR on Herb Analysis
- •3.10.15 Non-Destructive
- •3.10.16 Fast and Easy
- •3.10.17 Rich Information
- •3.10.18 Versatility
- •3.10.19 Cost-Effective
- •3.10.20 FTIR Limitations and Low Sensitivity
- •3.10.21 Overlapping Bands
- •3.10.22 Preparation of the Sample
- •3.10.23 Conclusion
- •3.11 Nuclear Magnetic Resonance Spectroscopy (NMR)
- •3.11.1 Sample Preparation and Instrumentation
- •3.11.2 One-Dimensional NMR Spectroscopy
- •3.11.3 Two-Dimensional NMR Spectroscopy
- •3.11.4 Phytochemical Applications
- •3.11.6 Techniques of Standardization
- •3.11.7 Extraction and Analysis of Bioactive Compounds
- •3.11.8 Conclusion
- •References
- •4.1 Introduction
- •4.2 Historical Context of Plant-Based Medicines
- •4.2.2 Development of Pharmacognosy
- •4.2.3 Impact of Plant-Based Medicines on Modern Pharmacology
- •4.3.1 Integration of Ethnobotanical Knowledge
- •4.3.2 Advanced Phytochemical Techniques
- •4.3.3 Bioassay-Guided Fractionation
- •4.3.4 Role of Metabolomics and Genomics
- •4.3.5 Integration of Nanotechnology
- •4.4 Ethnobotanical Approaches
- •4.4.1 Traditional Knowledge and Indigenous Applications
- •4.4.2 Ethnopharmacological Surveys and Their Relevance
- •4.5 Phytochemical Techniques
- •4.5.1 Methods of Plant Extraction and Isolation
- •4.5.1.1 Solvent Extraction
- •4.5.1.2 Supercritical Fluid Extraction (SFE)
- •4.5.1.3 Microwave-Assisted Extraction (MAE)
- •4.5.1.4 Ultrasound-Assisted Extraction (UAE)
- •4.5.1.5 Enzyme-Assisted Extraction (EAE)
- •4.6 Bioassay-Guided Fractionation
- •4.6.1 Fractionation Techniques
- •4.6.2 Biological Assays
- •4.6.3 Iterative Purification
- •4.7.1 High-Performance Liquid Chromatography (HPLC)
- •4.7.2 Gas Chromatography-Mass Spectrometry (GC-MS)
- •4.7.3 Nuclear Magnetic Resonance (NMR) Spectroscopy
- •4.7.4 Fourier Transform Infrared (FTIR) Spectroscopy
- •4.7.5 Metabolomics and Genomics in Plant Drug Discovery
- •4.8 Role of Metabolomics in Identifying Bioactive Compounds
- •4.8.1 Identification of Bioactive Compounds
- •4.8.2 Explanation of Biosynthetic Pathways
- •4.8.3 Discovery of Biosynthetic Genes
- •4.8.4 Enhancement of Phytochemical Production
- •4.9 Case Studies of Genomic Applications in Drug Discovery
- •4.9.1 Case Study 1: Artemisinin Production in Artemisia annua
- •4.9.2 Case Study 2: Taxol Biosynthesis in Taxus spp.
- •4.9.3 Case Study 3: Resveratrol Production in Vitis vinifera
- •4.10 Biotechnological Advances
- •4.10.1 Tissue Culture and the Genetic Modification of Medicinal Plants
- •4.10.2 Sustainable Production of Phytochemicals through Biotechnology
- •4.10.3 Role of Synthetic Biology in Plant-Based Drug Development
- •4.11 Nanotechnology in Phytochemical Delivery
- •4.11.1 Enhancing the Bioavailability of Plant-Derived Drugs with Nanocarriers
- •4.11.1.1 Nanoparticles
- •4.11.1.2 Liposomes
- •4.11.1.3 Nanoemulsions
- •4.11.2 Targeted Delivery Systems Using Nanotechnology
- •4.11.2.1 Active Targeting
- •4.11.2.2 Passive Targeting
- •4.11.2.3 Multifunctional Nanocarriers
- •4.11.3 Case Studies of Nano-Formulated Phytochemicals
- •4.11.3.1 Curcumin-Loaded Nanoparticles
- •4.11.3.2 Quercetin-Loaded Liposomes
- •4.11.3.3 Resveratrol-Functionalized Gold Nanoparticles
- •4.11.3.4 Nanoemulsion Formulations of Essential Oils
- •4.12.1 Paclitaxel (Taxol)
- •4.12.2 Artemisinin
- •4.12.3 Morphine
- •4.12.4 Quinine
- •4.12.5 Challenges and Limitations in Plant-Based Drug Development
- •4.12.5.1 Complexity of Plant Extracts
- •4.12.5.2 Variability in Chemical Composition
- •4.12.5.3 Sustainable Sourcing and Conservation
- •4.12.5.4 Regulatory and Approval Processes
- •4.12.6 Intellectual Property and Benefit Sharing
- •4.13 Future Perspectives
- •4.13.1 Emerging Trends in Plant-Based Drug Discovery
- •4.13.2 Integrating Traditional Knowledge with Modern Science
- •4.13.3 Potential of Plant Genomics and Biotechnology
- •4.14 Conclusion
- •References
- •5.1 Introduction
- •5.2 Traditional Phytomedicine
- •5.3 Modern Phytomedicine
- •5.4 Synthesis and Purpose of Bioactive Compounds
- •5.5.1 Phenolic Compounds (PCs)
- •5.5.2 Terpenes
- •5.5.3 Nitrogen-Containing Compounds
- •5.6 Extraction of Bioactive Compounds
- •5.7 Role of Herbs in Drug Discovery
- •5.8 Global Trade of Herbal Medicines
- •5.9.1 Herbal Compounds for the Human Immune System
- •5.9.2 Bioactive Compounds in Herbs For Cancer Treatment
- •5.9.3 Bioactive Compounds for Neurodegenerative Diseases
- •5.9.4 Bioactive Compounds for Viral Diseases
- •5.9.5 Anti-Inflammatory Bioactive Compounds in Herbs
- •5.9.6 Antidiabetic Bioactive Compounds in Herbs
- •5.9.7 Antibiotics
- •5.10 Summary
- •References
- •6.1 Introduction
- •6.1.2 Antibiotic-Resistant Microorganisms
- •6.1.3 Necessity of Developing Natural Plant-Derived Drugs
- •6.2 Pharmacological Activities of Medicinal Plants
- •6.2.1 Antimicrobial Activity of Herbal Drugs
- •6.2.2 Anticancer Activity of Medicinal Herbs
- •6.2.3 Antiviral Activity of Medicinal Herbs
- •6.2.3.1 Medicinal Plants Exhibiting Antiviral Activity
- •6.2.4 Antioxidant Activity of Medicinal Herbs
- •6.2.5 Hepatoprotective Activity of Medicinal Herbs
- •6.2.6 Nervous System Activity of Medicinal Herbs
- •6.2.7 Anti-Inflammatory Activity of Medicinal Herbs
- •6.2.7.1 Mechanism of Action
- •6.2.8 Antipyretic Activity of Medicinal Herbs
- •6.2.8.1 Medicinal Plants Possessing Antipyretic Properties
- •6.2.9 Antiallergic Activity of Medicinal Herbs
- •6.2.10 Antidiabetic Activity of Medicinal Herbs
- •6.2.10.1 Medicinal Plants Possessing Antidiabetic Activity
- •6.2.11 Immunomodulatory Activity of Medicinal Herbs
- •6.3 Advantages of Medicinal Herbs
- •6.4 Disadvantages of Medicinal Herbs
- •6.5 Future Prospects of Medicinal Herbs
- •References
- •7.1 Introduction to Herbal Drug Discovery
- •7.1.1 History of Herbal Drug Discovery
- •7.2 Current trends in herbal drug discovery
- •7.2.1 Molecular and Genetic Study Levels
- •7.2.2 Molecular Pharmacognosy
- •7.2.3 Combination Therapy
- •7.2.4 Conservation and Propagation Strategies
- •7.2.5 Pharmacogenomics
- •7.2.6 Computational Resources for Drug Discovery
- •7.4.1 Metabolomics Approaches in Herbal Drug Discovery
- •7.4.2 Genomic Approaches
- •7.5.1 Quinine for Malarial Treatment
- •7.5.2 Aspirin for Pain and the Treatment of Inflammation
- •7.6 Limitations in Herbal Drug Discovery
- •7.6.1 Regulatory Hurdles
- •7.6.2 Emerging Technologies
- •References
- •8.1 Introduction
- •8.2 Traditional Approaches to Herbal Formulation
- •8.3 Phytochemical Constituents in Herbal Formulations
- •8.3.1 Alkaloids
- •8.3.2 Flavonoids
- •8.3.3 Terpenoids
- •8.3.4 Glycosides
- •8.3.5 Tannins
- •8.3.6 Phenolic Acids
- •8.3.7 Saponins
- •8.4 Modern Extraction Techniques in Herbal Formulation
- •8.4.1 Solvent Extraction
- •8.4.2 Supercritical Fluid Extraction (SFE)
- •8.4.3 Ultrasonic Extraction
- •8.4.4 Microwave-Assisted Extraction (MAE)
- •8.4.5 Enzyme-Assisted Extraction (EAE)
- •8.4.6 Comparative Analysis of Extraction Techniques
- •8.5 Advanced Formulation Strategies
- •8.5.1 Nanotechnology in Herbal Formulations
- •8.5.1.1 Nanoemulsions
- •8.5.1.2 Liposomes
- •8.5.1.3 Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs)
- •8.5.2 Encapsulation Techniques
- •8.5.2.1 Microencapsulation
- •8.5.2.2 Coacervation
- •8.5.2.3 Spray Drying
- •8.5.3 Standardized Extracts
- •8.5.3.1 Methods of Standardization
- •8.5.3.2 Challenges in Standardization
- •8.5.4 Synergistic Formulations
- •8.5.4.1 Mechanisms of Synergy
- •8.5.4.2 Examples of Synergistic Formulations
- •8.5.5 Personalized Herbal Formulations
- •8.5.5.1 Role of Genomics in Personalized Herbal Medicine
- •8.5.5.2 Challenges in Personalized Herbal Formulations
- •8.6.1 Recognition and Verification of Herbal Materials
- •8.6.1.4 DNA Barcoding
- •8.6.2 Use of Reference Standards
- •8.6.2.1 Primary and Secondary Reference Standards
- •8.6.2.2 Development of Reference Standards
- •8.6.3 Good Manufacturing Practices (GMP)
- •8.6.3.1 Sourcing and Handling of Raw Materials
- •8.6.3.2 Manufacturing Processes
- •8.6.3.3 Quality Control Testing
- •8.6.3.4 Documentation and Record-Keeping
- •8.7 Challenges in Herbal Formulation Development
- •8.7.1 Variability in Chemical Composition
- •8.7.1.1 Factors Affecting Chemical Composition
- •8.7.1.2 Strategies to Address Variability
- •8.7.2 Complexity of Herbal Extracts
- •8.7.2.1 Analytical Challenges
- •8.7.2.2 Formulation Challenges
- •8.7.3 Standardization of Herbal Formulations
- •8.7.3.1 Challenges in Standardization
- •8.7.3.2 Advances in Standardization
- •8.7.4 Regulatory Hurdles
- •8.7.4.1 Regulatory Requirements
- •8.7.4.2 Challenges in Meeting Regulatory Requirements
- •8.7.4.3 Strategies to Overcome Regulatory Hurdles
- •8.8 Future Directions in Herbal Formulation Development
- •8.8.1 Artificial Intelligence and Machine Learning
- •8.8.1.1 Applications in Herbal Formulation Development
- •8.8.1.2 Challenges and Opportunities
- •8.8.2 Integration of Omics Technologies
- •8.8.2.1 Applications in Herbal Medicine
- •8.8.2.2 Challenges and Opportunities
- •8.8.3 Novel Delivery Systems
- •8.8.3.1 Nanotechnology in Herbal Medicine
- •8.8.3.2 Other Novel Delivery Systems
- •8.8.3.3 Challenges and Opportunities
- •8.9 Conclusion
- •References
- •9.1 Introduction
- •9.2 Herbal Nanotechnology and Phytonanomedicines
- •9.2.1 Role of Phytonanomedicines in Disease Management
- •9.2.1.1 Cancer
- •9.2.1.2 Diabetes Mellitus
- •9.2.1.3 Neurodegenerative Diseases (NDDs)
- •9.2.1.4 Cardiovascular Diseases (CVD)
- •9.3 Nanoparticles for Plant Disease Management
- •9.3.1 Role of Silver Nanoparticles (AgNPs) in Plant Disease Management
- •9.3.2 Role of Gold Nanoparticles (AuNPs) in Plant Disease Management
- •9.3.3 Role of Zinc Nanoparticles (ZnNPs) in Plant Disease Management
- •9.3.4 Role of Palladium Nanoparticles (PdNPs) in Plant Disease Management
- •9.3.5 Role of Titanium Nanoparticles (TiNPs) in Plant Disease Management
- •9.3.6 Role of Iron Nanoparticles (FeNPs) in Plant Disease Management
- •9.3.7 Role of Copper Nanoparticles (CuNPs) in Plant Disease Management
- •9.3.8 Role of Selenium Nanoparticles (SeNPs) in Plant Disease Management
- •9.4 Nanoparticles as Carriers
- •9.4.1 Nanoparticles as Carriers for Insecticides
- •9.4.2 Nanoparticles as Carriers for Fungicides
- •9.4.3 Nanoparticles as Carriers for Herbicides
- •9.4.4 Role of Nanoparticles and RNAi in Plant Disease Management
- •References
- •10.1 Introduction
- •10.2 Types of Nanomaterials Utilized in Herbal Pharmaceuticals
- •10.2.1 Nanoparticles
- •10.2.2 Nanocapsules
- •10.2.3 Nanospheres
- •10.2.4 Nanotubes
- •10.3 Innovative Applications of Nanotechnology
- •10.3.1 Anti-Cancer Herbal Nanomedicine
- •10.3.2 Anti-Inflammatory Herbal Nanomedicine
- •10.3.3 Antibacterial Herbal Nanomedicine
- •10.3.4 Antifungal Herbal Nanomedicine
- •10.3.5 Antioxidant Neuroprotective Herbal Nanomedicine
- •10.3.6 Anti-Diabetic Herbal Nanomedicine
- •10.3.7 Cardioprotective Herbal Nanomedicine
- •10.4.1 Combining Nanotechnology and Herbal Pharmacotherapy
- •10.4.2 Enhanced Bioavailability
- •10.4.3 Targeted Delivery
- •10.4.4 Improved Stability or Shelf Life
- •10.4.5 Synergistic Effects and Combination Therapies
- •10.4.6 Reduced Dosage and Toxicity
- •10.4.7 Crossing Biological Barriers
- •10.5 Challenges and Limitations
- •10.5.1 Complexity of Herbal Systems
- •10.5.2 Bioavailability Enhancement
- •10.5.3 Regulatory and Ethical Considerations
- •10.5.4 Cost and Scalability
- •10.5.5 Safety and Toxicity Issues
- •10.5.6 Standardization and Quality Control
- •10.6 Future Prospects and Trends
- •10.7 Conclusion
- •References
- •11. Nanoparticle Synthesis and Characterization for Herbal Drug Delivery
- •11.1 Introductions
- •11.2 Background and Literature Review
- •11.2.1 Historical Overview and Present Trends in Herbal Medicine
- •11.2.2 Overview of Nanoparticles in Drug Delivery
- •11.2.3 Advantages of Nanoparticle-Based Drug Delivery Systems
- •11.3.1 Polymer Nanoparticle
- •11.3.2 Metallic Nanoparticles
- •11.3.3 Magnetic Nanoparticles
- •11.3.4 Liposomes
- •11.3.5 Dendrimers
- •11.3.6 Niosomes
- •11.3.7 Proniosomes
- •11.3.8 Phytosomes
- •11.3.9 Transfersomes
- •11.3.10 Microspheres
- •11.3.11 Ethosomes
- •11.4 Nanoparticle Synthesis Techniques
- •11.4.1 Top-Down Approach
- •11.4.2 Bottom-Up Approach
- •11.4.3 Chemical Methods
- •11.4.3.1 Sol-Gel Method
- •11.4.3.2 Spinning
- •11.4.3.3 Microemulsion Technique
- •11.4.3.4 Hydrothermal Synthesis
- •11.4.3.5 Electrochemical Synthesis
- •11.4.3.6 Polyol Synthesis
- •11.4.3.7 Thermal Decomposition
- •11.4.3.8 Chemical Vapor Deposition & Chemical Vapor Synthesis
- •11.4.3.9 Plasma-Enhanced Chemical Vapor Deposition
- •11.4.4 Physical Methods
- •11.4.4.1 High-Energy Ball Milling Process
- •11.4.4.2 Physical Vapor Deposition (PVD)
- •11.4.4.3 Pyrolysis
- •11.4.4.4 Melt Mixing
- •11.4.4.5 Laser Ablation (LA) and Pulse Laser Deposition (PLD)
- •11.4.4.6 Electron Beam Evaporation (EBE)
- •11.4.4.7 Inert Gas Condensation (IGC)
- •11.4.4.8 Flame Spray Pyrolysis (FSP)
- •11.4.4.9 Laser Pyrolysis
- •11.4.4.10 Nanolithography
- •11.4.4.11 Electrospraying Technique
- •11.4.5 Biosynthesis of Nanoparticles
- •11.4.5.1 Utilizing Biomolecules as Templates for Synthesis
- •11.4.5.2 Microbial Synthesis
- •11.4.5.3 Utilizing Botanical Extracts for Synthesis
- •11.4.6 Mechanical Techniques
- •11.5 Characterization of Nanoparticles
- •11.5.1 Chemical
- •11.5.2 Physical
- •11.5.2.1 Particle Size Analyzer
- •11.5.2.2 Surface Area Analysis
- •11.5.2.3 Zeta Potential
- •11.5.2.4 Thermogravimetric Analysis (TGA)
- •11.5.2.5 Dynamic Light Scattering
- •11.5.2.6 Scanning Electron Microscopy (SEM)
- •11.5.2.7 Nuclear Magnetic Resonance
- •11.5.2.8 Transmission Electron Microscopy (TEM)
- •11.5.2.9 X-Ray Powder Diffraction (XRD)
- •11.5.2.10 Evaluation of Recovery and Encapsulation Performance
- •11.5.2.11 Atomic Force Microscopy
- •11.5.2.12 UV-Visble Spectroscopy
- •11.5.2.13 Surface Plasmon Resonance
- •11.5.2.14 Acoustic Methods
- •11.6 Conclusion
- •References
- •12.1 Introduction
- •12.1.1 Challenges of Herbal Extracts in Traditional Medicine
- •12.1.2 Importance of Bioavailability in Therapeutic Efficacy
- •12.1.3 The Role of Nanotechnology in Addressing Bioavailability Issues
- •12.2 Principles of Bioavailability Enhancement
- •12.2.1 Understanding ADME Profiles
- •12.2.1.1 Absorption
- •12.2.1.1.1 Distribution
- •12.2.1.1.2 Metabolism
- •12.2.1.1.3 Excretion
- •12.2.2 Factors Affecting the Bioavailability of Herbal Compounds
- •12.2.2.1 Absorption within the GI Lumen
- •12.2.2.1.1 The Solubility of the Herbal Products
- •12.2.2.1.2 Absorption via Passive Diffusion
- •12.2.2.2 Metabolism
- •12.2.2.2.1 Metabolism Prior to Absorption
- •12.2.2.2.2 Metabolism Post-Absorption
- •12.2.2.3 Mechanisms of Action for Nanocarriers
- •12.3 Types of Nanocarriers and Their Applications
- •12.3.1 Liposomes: Structure, Function, and Applications
- •12.3.1.1 Structure
- •12.3.1.2 Function
- •12.3.1.3 Applications
- •12.3.2 Polymeric Nanoparticles: Design and Delivery Mechanisms
- •12.3.2.1 Design
- •12.3.2.1.1 Polymeric Material
- •12.3.2.1.2 Drug Encapsulation Methods
- •12.3.2.1.2.1 Solvent Evaporation
- •12.3.2.2 The Delivery Mechanism of the Drug
- •12.3.2.2.1 Route of Delivery
- •12.3.2.2.2 Targeting Strategies
- •12.3.2.2.2.1 Passive Targeting
- •12.3.2.2.2.2 Active Targeting
- •12.3.2.2.2.3 Stimuli-Responsive Targeting
- •12.3.2.2.3 Drug Release
- •12.3.2.2.3.1 Diffusion-Controlled Release
- •12.3.2.2.3.2 Solvent-Controlled Release
- •12.3.2.2.3.3 Chemical Interaction-Based Release
- •12.3.2.2.3.4 Temperature-Controlled Release
- •12.3.3 Nanoemulsions: Formulation and Stability
- •12.3.3.1 Formulation
- •12.3.3.1.1 The Generation of Nanoemulsion
- •12.3.3.2 Stability
- •12.3.3.2.1 Physical Stability
- •12.3.3.2.2 Chemical Stability
- •12.3.4 Micelles: Enhancing Solubility and Bioavailability
- •12.3.4.1 Enhancing Solubility and Bioavailability
- •12.3.4.1.1 Micellar Solubilization
- •12.3.4.1.2 Polymeric Micellar Nanocarriers
- •12.4 Nanocarriers and Solubility Enhancement
- •12.4.1 Techniques for Improving the Solubility of Hydrophobic Compounds
- •12.4.1.1 Lipid Dispersion Techniques
- •12.5 Stability of Herbal Extracts in Nanocarrier Systems
- •12.5.1 Protection against Degradation and Oxidation
- •12.5.2 Example of Stability Improvement in Herbal Extracts
- •12.5.2.2 Example 2: Enhancing Curcumin Stability and Bioavailability using SLNs
- •12.6 Targeted Delivery and Controlled Release
- •12.6.1 Key Principles
- •12.6.1.2 Design and Composition of Nanocarriers
- •12.6.1.2.1 Integration and Optimization
- •12.6.1.2.2 Advantages of Controlled Release Systems
- •12.6.1.2.3 Applications in Medicine
- •12.7 Pharmacokinetics and Pharmacodynamics
- •12.7.1 Enhancing Therapeutic Efficacy through Pharmacokinetic Modulation
- •12.7.1.1 Sustained Release and Targeted Delivery
- •12.7.1.2 Improved Bioavailability and Reduced Inter-Individual Variability
- •12.7.1.3 Enhanced Pharmacodynamic Effects
- •12.7.1.4 Reduced Adverse Effects and Toxicity
- •12.7.1.5 Opportunities for Personalized Medicine
- •12.7.2 Clinical Implications of Improved Pharmacodynamics
- •12.8 Clinical Applications and Case Studies
- •12.8.1 Successful Implementations of Nanocarrier-Based Herbal Drugs
- •12.8.1.1 Curcumin-Loaded Nanoparticles
- •12.8.1.2 Quercetin-Loaded Liposomes
- •12.8.1.3 Ginger Extract Nanocarriers
- •12.8.1.4 Green Tea Extract Nanocarriers
- •12.8.2 Challenges and Limitations in Clinical Settings
- •12.8.2.1 Quality Control and Standardization
- •12.8.2.2 Limited Encapsulation Capacity
- •12.8.2.3 Pharmacokinetic and Pharmacodynamic Variability
- •12.8.2.4 Manufacturing Challenges
- •12.9 Future Perspectives
- •12.9.1 Advancing Nanocarrier Design and Engineering
- •12.9.2 Expanding the Diversity of Herbal Extracts Formulated with Nanocarriers
- •12.9.3 Advancing Preclinical and Clinical Evaluation
- •12.9.4 Addressing Regulatory and Commercialization Challenges
- •12.9.5 Exploring Synergies with Other Emerging Technologies
- •12.10.1 Opportunities
- •12.10.2 Challenges
- •12.11 Conclusion
- •References
- •13.1 Introduction to Herbal Medicine and Neurological Diseases
- •13.1.1 Overview of Herbal Medicine
- •13.1.1.1 Key Aspects of Herbal Medicine
- •13.1.2 Scope of Neurological Diseases
- •13.1.3 Rationale for Exploring Herbal Remedies
- •13.2 Neuroprotective Effects of Herbal Compounds
- •13.2.1 Mechanisms of Neuroprotection
- •13.2.1.1 Antioxidant Activity
- •13.2.1.3 Inhibition of Excitotoxicity
- •13.2.1.4 Enhancement of Neurogenesis and Synaptic Plasticity
- •13.2.1.5 Mitochondrial Protection
- •13.2.2 Role of Oxidative Stress in Neurological Diseases
- •13.2.2.1 Essential Components of Oxidative Stress in Neurological Disorders
- •13.2.2.1.1 Impaired Functioning of Mitochondria
- •13.2.2.1.2 Neurological Disorders Linked to Oxidative Stress
- •13.2.3 Anti-Inflammatory Properties of Herbal Compounds
- •13.2.3.2 Uses and Advantages
- •13.2.4 Regulation of Neuronal Apoptosis by Herbal Remedies
- •13.2.4.1 Neurological Diseases Applications
- •13.2.4.2 Future Scope and Challenges of Therapy
- •13.3.1 Importance of Neurogenesis in Brain Repair
- •13.3.2 Effects of Herbal Extracts on Neurogenesis
- •13.3.3 Enhancement of Synaptic Plasticity by Herbal Compounds
- •13.4 Herbal Medicine as Adjunctive Therapy
- •13.4.1 Synergistic Effects of Herbal Compounds with Conventional Treatments
- •13.4.1.1 Cancer Care
- •13.4.1.2 Depression Relief
- •13.4.1.3 Heart Health
- •13.4.1.4 Diabetes Management
- •13.4.1.5 Pain Relief
- •13.4.2 Mitigation of Drug-Induced Side Effects
- •13.4.2.1 Digestive Challenges
- •13.4.2.2 Liver Safeguarding
- •13.4.2.3 Kidney Protection
- •13.4.2.4 Neurotoxicity
- •13.4.2.5 Cardiotoxicity
- •13.4.2.6 Bone Marrow Suppression
- •13.4.2.7 Managing Fatigue
- •13.4.3 Enhancement of Therapeutic Outcomes
- •13.5 Future Directions and Challenges
- •13.5.1 Opportunities for Further Research
- •13.5.2 Challenges in Herbal Medicine Research
- •13.5.3 Integration of Traditional Knowledge with Modern Science
- •13.6 Case Studies and Clinical Applications
- •13.6.1 Illustrative Case Studies
- •13.6.2 Clinical Applications of Herbal Medicine in Neurological Diseases
- •13.7 Conclusion
- •13.7.1 Summary of Key Findings
- •13.7.2 Future Outlook for Herbal Medicine in Neurology
- •References
- •14.1 Introduction
- •14.1.2.1 Physiochemical Characteristics and Biological Interactions
- •14.1.2.2 Potential Toxicity Concerns
- •14.1.2.3 Regulatory and Ethical Considerations
- •14.2 Preclinical Safety Assessment
- •14.2.1 In vitro Toxicity Testing
- •14.2.2 In vivo Animal Studies
- •14.2.3 Evaluating the Pharmacokinetics and Biodistribution of Nanoparticles
- •14.2.4 Immunogenicity and Biocompatibility Testing
- •14.3 Toxicological Profiling
- •14.3.1 Identification and Characterization of Possible Toxins
- •14.3.1.1 Nanoparticle Components
- •14.3.1.2 Contaminants and Impurities
- •14.3.1.3 Herbal Compounds
- •14.3.2 Dose–Response Relationships
- •14.4 Chronic Toxicity and Carcinogenicity Studies
- •14.4.1 Genotoxicity and Mutagenicity Testing
- •14.5 Clinical Safety Assessment
- •14.5.1 Phases of Clinical Trials for Nanoparticle-Based Herbal Formulation
- •14.5.2 Monitoring Adverse Effects and Long-Term Safety in Human Subjects
- •14.5.2.1 Initial Reporting Systems
- •14.5.2.2 Clinical Monitoring
- •14.5.2.3 Pharmacovigilance Networks
- •14.5.2.4 Regular Safety Updates
- •14.5.2.5 Post-Marketing Studies
- •14.5.2.6 Pharmacogenomics Studies
- •14.5.3 Post-Market Surveillance and Pharmacovigilance
- •14.5.3.1 Real-World Evidence Collection
- •14.5.3.2 Active Surveillance Programs
- •14.5.3.3 Signal Detection
- •14.5.3.4 Risk Communication
- •14.5.3.5 Regulatory Actions
- •14.6 Analytical Techniques for Safety Assessment
- •14.6.1 Advanced Imaging and Spectroscopy Methods
- •14.6.1.1 Transmission Electron Microscopy (TEM)
- •14.6.1.2 Scanning Electron Microscopy (SEM)
- •14.6.1.3 Infrared Spectroscopy (IRS)
- •14.6.2 Nanoparticle Tracking and Quantification
- •14.6.2.1 Nanoparticle Tracking Analysis (NTA)
- •14.6.2.2 Dynamic Light Scattering (DLS)
- •14.6.3 Surface Characterization and Stability Analysis
- •14.6.3.1 X-Ray Photoelectron Spectroscopy (XPS)
- •14.6.3.2 Differential Scanning Calorimetry (DSC)
- •14.6.4 High-Throughput Screening Technologies
- •14.6.4.1 Cell-Based Assay
- •14.6.4.2 Genotoxicity Screening
- •14.7 Regulatory Frameworks and Guidelines
- •14.7.1 International and National Regulatory Frameworks
- •14.7.1.1 Regulation Management
- •14.7.1.2 Risk Analysis
- •14.7.1.3 Labelling and Informed Consent
- •14.7.1.4 International Standards
- •14.7.1.5 Regulation in Research and Development
- •14.7.2 Risk Assessment Models and Safety Thresholds
- •14.7.2.1 Invitro Toxicity Assay
- •14.7.2.2 Green Algorithms
- •14.7.2.3 Nanoprobes for Measuring ROS
- •14.8 Risk Mitigation Strategies
- •14.8.1 Designing Safer Nanoparticle-Based Formulations
- •14.8.2 Controlled Release Systems and Targeted Delivery
- •14.8.3 Reducing Off-Target Effects and Enhancing Selectivity
- •14.8.3.1 Nanoparticle-Based Systems for Intracellular Targeting
- •14.8.4 Engineering Biodegradable and Biocompatible Nanoparticles
- •14.9 Case Studies of Safety Assessment
- •14.9.1 Successful Examples of Safe Nanoparticle-based Herbal Formulations
- •14.9.1.1 Curcumin-Loaded Nanoparticles
- •14.9.1.2 Green Tea Polyphenol (EGCG) Nanoparticles
- •14.9.2 Lessons Learned from Safety Failures and Recalls
- •14.10 Ethical Considerations
- •14.10.1 Ethical Issues in Nanotoxicology Research
- •14.10.2 Informed Consent and Patient Safety in Clinical Trials
- •14.11 Conclusion
- •References
- •15. Novel Drug Delivery Methods for Herbal Medicine
- •15.1 Introduction
- •15.2 Novel Drug Delivery Approaches
- •15.3 Potential of Novel Drug Delivery for Herbal Drugs
- •15.4 Types of Novel Herbal Drug Delivery Systems
- •15.4.1 Mouth-Dissolving Tablets
- •15.4.2 Controlled-Release Formulations
- •15.4.3 Liposomes
- •15.4.4 Phytosomes
- •15.4.5 Nanoparticles
- •15.4.6 Niosomes
- •15.4.7 Proniosomes
- •15.4.8 Transdermal Drug Delivery System
- •15.4.9 Microspheres
- •15.4.10 Emulsions
- •15.4.11 Ethosomes
- •15.4.12 Other Novel Approaches
- •15.5 Future Opportunities and Challenges
- •15.6 Conclusion
- •References
- •16.1 Fundamentals of Herbal Drug Delivery Systems
- •16.1.1 Advantages of Herbal Drugs
- •16.1.2 Challenges of Herbal Drugs
- •16.1.3 Rise of Targeted Delivery for Herbal Drugs
- •16.2 Carriers Systems for Targeted Drugs
- •16.2.1 Liposome-Mediated Drug Delivery System
- •16.2.2 Polymeric Nanoparticles as Drug Carriers
- •16.2.3 Micelles
- •16.2.4 Dendrimers
- •16.2.5 Carbon Nanotubes and Fullerenes
- •16.2.6 Phytosomes
- •16.2.7 DNA Nanocarriers for Targeted Drug Delivery
- •16.2.8 Aptamers for Drug Targeting
- •16.2.9 Microspheres and Micropellets
- •16.3 Targeting Strategies and Mechanisms
- •16.3.1 Ligand-Receptor Mediated Targeting
- •16.3.2 Antibody Drug Conjugates
- •16.3.3 Aptamers for a Targeted Delivery System for Herbal Drugs
- •16.3.4 Stimuli-Responsive Delivery Systems
- •16.4.1 Herbal Drugs for Communicable Diseases
- •16.4.2 Herbal Drugs for Communicable and Non-Communicable Diseases
- •16.5 Conclusion and Future Perspective
- •References
- •17.1 Introduction
- •17.2 An Overview of Phytomedicine
- •17.3 Application of Nanoformulation
- •17.3.1 Nanosuspension Technology
- •17.3.2 Nano-Encapsulation
- •17.3.3 Three-Dimensional Printing in Nanopharmacy (Nano Printing)
- •17.3.4 Applications in Drug Delivery Systems
- •17.3.5 Biomimetics and Bioinspiration in Nanopharmaceuticals/Nanomedicines
- •17.3.6 Green Design
- •17.4 Future study
- •17.5 Conclusion
- •References
- •18.1 Introduction
- •18.2 Herbal Phytoconstituents for Disease Management
- •18.3 Barriers to Herbal Formulations
- •18.4 Strategies to Enhance Bioavailability
- •18.5 Herbal Formulations – Conventional Dosage Forms
- •18.6 Nanocarriers in Herbal Drug Delivery
- •18.7 Clinical Status of Current Delivery Strategies
- •18.8 Conclusion
- •References
- •19.1 Introduction
- •19.1.1 Definition and Scope
- •19.1.2 History
- •19.1.3 Importance and Relevance in Modern Medicine
- •19.2 Basics of Nanotechnology and Herbal Medicines
- •19.2.1 Nanotechnology
- •19.2.2 Basics of Herbal Medicines
- •19.3 Implementing Herbal Nanomedicines
- •19.3.1 Protocols for Implementation
- •19.3.1.1 Techniques for the Preparation of Herbal Nanoparticles
- •19.3.1.2 Dosage and Administration Strategies
- •19.3.2 Documenting Patient Case Histories and its Analysis
- •19.3.2.1.1 Condition Treated
- •19.3.2.1.2 Treatment Provided
- •19.3.2.1.3 Patient Response
- •19.4 Standardized Treatment Procedures
- •19.4.1 Customization for Specific Ailments
- •19.4.2 Tailoring for Individual Patient Needs
- •19.5 Advantages of Herbal Nanomedicine in Clinical Settings
- •19.5.1 Increased Patient Adherence
- •19.5.2 Reduced Side Effects
- •19.5.3 Improved Efficacy
- •19.6 The Future of Herbal Nanomedicine in Clinical Practice
- •References
- •20.1 Herbal Nanomedicines: A Brief Overview
- •20.2 Safety Issues and Toxicological Concerns with Herbal Nanomedicines
- •20.3.1 In Vitro Methods
- •20.3.2 In Vivo Assays
- •20.3.3 Utilization of Advanced Analytical Tools
- •20.3.4 In Silico Approach: Nano-QSAR
- •20.3.5 Grouping/Read-Across Technique
- •20.3.6 Genetic Approaches
- •20.3.7 Utilization of Validated Human Cell Lines in Immunotoxicity Assays
- •20.3.8 In Vitro Carcinogenicity Assessment with Transformed Cells
- •20.3.9 DNA Barcoding
- •20.3.10 Systems Toxicology: ‘Omics’ Technology
- •20.3.11 Nano-Informatics Database
- •20.3.12 Miscellaneous Advanced Approaches in Nanotoxicology Assessment
- •20.7 Conclusion
- •Acknowledgement
- •References
- •21.1 Introduction
- •21.2 Global Regulatory Landscape
- •21.3 Regulatory Agencies and Their Roles
- •21.3.1 United States
- •21.3.1.1 Key Responsibilities of the FDA
- •21.3.2 Canada
- •21.3.3 Europe
- •21.3.3.1 European Medicine Agency
- •21.3.3.2 Key Responsibilities of the European Medicine Agency
- •21.3.3.3 Quality Guidelines of the European Medicine Agency
- •21.3.3.3.1 The Declaration of Herbal Preparations in Traditional Herbal Medicinal Products
- •21.3.3.3.2 Practices for Materials Collection from Herbal Origin
- •21.3.4 Non-Clinical Guidelines
- •21.3.4.1 Genotoxicity Assessment of Herbal Preparations
- •21.3.5 Asia
- •21.3.5.1 Traditional Chinese Medicines
- •21.3.5.2 Regulatory Approaches for TM/CM
- •21.3.6 Indian Ayurvedic Regulations
- •21.3.6.1 Food Safety and Standards Authority of India
- •21.3.7 World Health Organization
- •21.3.7.1 WHO Guidelines on the Safety Monitoring of Herbal Medicines
- •21.4 Classification of Herbal Products
- •21.4.1 Dietary Supplements
- •21.4.2 Herbal Supplements
- •21.4.3 Functional Food
- •21.4.4 Traditional Medicine
- •21.5 Approval Process
- •21.5.1 Pre-Market Approval
- •21.5.2 Post-Market Surveillance
- •21.5.3 Clinical Trials
- •21.6 Diverse Regulatory Standards
- •21.6.1 Example of Divergence
- •21.7 Efforts for International Collaboration
- •21.8 Impact of Scientific Advancements
- •21.8.1 Combination of Modern Research and Traditional Knowledge
- •21.8.2 Recognizing the Value of Traditional Knowledge
- •21.9 Approaches to Integration
- •21.9.1 Collaborative Research
- •21.9.2 Participatory Research
- •21.9.3 Interdisciplinary Research
- •21.9.4 Comparative Research
- •21.10 Challenges & Considerations
- •21.11 Advanced Technologies in Quality Control
- •21.11.1 Analytical Techniques
- •21.11.2 Good Manufacturing Practices (GMP)
- •21.11.3 Biological Assays
- •21.11.4 Standardization of Extraction Methods
- •21.11.5 Data Management & Traceability
- •21.12 Challenges & Future Directions
- •21.13 Personalized Herbal Medicine
- •21.14 Regulatory Implications
- •21.15 Sustainable and Ethical Sourcing
- •21.16 Conclusion
- •21.17 Future Outlook for the Regulatory Framework
- •References
- •22. Present Challenges and Future Perspective of the Herbal Drug Industry
- •22.1 Introduction
- •22.2 Emerging Trends and Innovations
- •22.2.1 Biotechnology and Genetic Engineering
- •22.2.2 Nanotechnology
- •22.3 Regulatory Challenges and Opportunities
- •22.4 Intellectual Property Rights
- •22.4.1 Conventional Medicine and Rights to Intellectual Property
- •22.5 Global Market Trends
- •22.6 Challenges and Limitations
- •22.7 Future Directions
- •22.8 Conclusions
- •References
- •Index

344 Herbal Pharmacopeia
Shen, Y.J., Zhang, Z.W., Luo, X.G., Wang, X.F., & Wang, H.L. (2008). Nanoparticles of traditional Chinese
herbs inhibit thrombosis in vivo. Haematologica, 93, 1457.
Shukla, N.D., & Tiwari, M. (2011). Proniosomal drug delivery systems – Clinical applications. Int J Res
Pharmaceut Biomed Sci, 2, 880–7.
Song, Y.M., Ping, Q.N., & Wu, Z.H. (2005). Preparation of silybin nano emulsion and its pharmacokinetics in
rabbits. J Chin Pharm Univ, 5, 427–31.
Sterer, N., Nuas, S., Mizrahi, B., Goldenberg, C., Weiss, E.I., Domb, A, et al. (2008). Oral malodor reduction
by a palatal mucoadhesive tablet containing herbal formulation. J Dent, 36, 535–9.
Sungthongjeen, S., Puttipipatkhachorn, S., Paeratakul, O., Dashevsky, A., & Bodmeier, R. (2004). Development
of pulsatile release tablets with swelling and rupturable layers. J Control Release, 95, 147–59.
Suresh, S., & Jain, V. (2016). Recent advances in herbal drug delivery systems and the challenge of bioavail-
ability. J Pharm Sci, 105(8), 2505–2512.
Tangri, P., & Khurana, S. (2011). Niosomes: Formulation and evaluation. Int J Biopharm, 2, 47–53.
Tanwar, Y.S., Gupta, G.D., & Ramawa, K.G. (2006). Development and evaluation of microparticles of
Gugulipid. The Pharma Review. New Delhi: Kongposh Publications Pvt., Ltd., p. 124–32.
Touitou, E., Godin, B., Dayan, N., Weiss, C., Piliponsky, A., & Levi- Schaffer, F., et al. (2001). Intracellular
delivery mediated by an ethosomal carrier. Biomaterials, 22, 3053–9.
Verma, M., Gupta, P.K., Varsha, B.P., & Purohit, A.P. (2007). Development of transdermal drug dosage formu-
lation for the anti- rheumatic ayurvedic medicinal plants. Anc Sci Life, 11, 66–9.
Vicentini, F.T., Simi, T.R., Del Ciampo, J.O., Wolga, N.O., Pitol, D.L., & Iyomasa, M.M., et al. (2008).
Quercetin in w/o microemulsion: In vitro and in vivo skin penetration and efcacy against UVB- induced
skin damages evaluated in vivo. Eur J Pharm Biopharm, 69, 948–57.
Wagner, V., Dullaart, A., Bock, A.-K., & Zweck, A. (2006). The emerging nanomedicine landscape. Nat Biotechnol,
24(10), 1211–1217.
Walve, J.R., Bakliwal, S.R., Rane, B.R., & Pawar, S.P. (2011). Transfersomes: A surrogated carrier for trans-
dermal drug delivery system. Int J Appl Biol Pharm Technol, 2, 204–13.
Xiao- Ying, L., Luo, J.B., Yan, Z.H., Rong, H.S., & Huang, W.M. (2006). Preparation and in vitro and in vivo
evaluations of topically applied capsaicin transfersomes. Zhongguo Zhong Yao Za Zhi, 31, 981–4.
Zhao, H.R., Wang, K., Zhao, Y., & Pan, L.Q. (2002). Novel sustained- release implant of herb extract using
chitosan. Biomaterials, 23, 4459–62.
Zhaowu, Z., Xiaoli, W., Yangde, Z., & Nianfeng, L. (2009). Preparation of matrine ethosome, its percutaneous
permeation in vitro and anti- inammatory activity in vivo in rats. J Liposome Res, 19, 155–62.
Zhong, H., Deng, Y., Wang, X., & Yang, B. (2005). Multivesicular liposome formulation for the sustained deliv-
ery of breviscapine. Int J Pharm, 301, 15–24.

Targeted Delivery Systems
16
forHerbal Drugs
Rizwan Ullah Khan and Syeda Pakeeza Fatima Naqvi
Institute of Chemical Sciences, Gomal University, D.I. Khan, Pakistan
Yubao Chen
Deputy Secretary General, Chinese Society of Biotechnology, China
Sohail Ahmad
Gomal Center of Biochemistry and Biotechnology, Gomal University,
Dera Ismail Khan, Pakistan
16.1 FUNDAMENTALS OF HERBAL DRUG DELIVERY SYSTEMS
In recent years, herbal medicines have gained the worldwide attention of peoples and researchers
due to their esthetic value, increased patient compliance and prominent therapeutic effects. Novel
drug delivery systems for the delivery of herbal drugs possesses several advantages over conventional formulations. These include, among others, the enhancement of solubility, bioavailability, and
protection from toxicity (Prajakta N. Dongare et al., 2021). The herbal drugs can be used in a more
upright course with enhanced efcacy by incorporating them into suitable dosage forms (Guo et al.,
2023). This can be achieved by designing novel drug delivery systems for such drugs. Such systems
include liposomes, polymeric nanoparticles, micelle, nanocapsules, phytosomes, carbon nanotubes,
DNA nano carriers, and aptamers- based delivery.
There has been an increased advancement in the eld of herbal drug delivery systems, especially
with the incorporation of the nanotechnology. This integration is intended to improve the solubility,
effectiveness, and safety of the herbal products in which the different active compounds often have
low solubility and bioavailability levels because of their complex molecular structures. Many of the
preventive and curative formulations in the traditional system demand a greater amount of drugs to
produce the desired therapeutic efcacy which invariably leads to more side effects and poor patient
compliance. Some challenges require to be overcome in the development of herbal drugs through
nanotechnology, which may enhance the pharmacokinetic properties of herbal extracts and deliver
them to precise sites within the body. The application of nanotechnology in the herbal drug delivery
system (HDDS) can effectively address these challenges. Nanotechnology- based drug delivery systems (NDDS) have been proven to be a revolutionary strategy to improve the medicinal efcacy of
herbal drugs. These systems employ carriers in the nano range that are created using liposomes,
solid lipid nanoparticles (SLNs), and polymeric nanoparticles to encapsulate valuable active constituents present in herbs. Moreover, it helps to enhance the efcacy prole of the active compounds
mainly due to improved stability, solubility and bioavailability. This is because it has been discovered that nanoparticles of comparatively insoluble herbal extracts could improve their biopharmaceutical properties; in other words, the bioavailability of the compound, thereby optimizing
therapeutic efciency for minimum dosing (Jalili et al., 2023; Dewi et al., 2022; Verma et al., 2018).
Further, it offers exibility in minimizing the frequency of administration which may ease the
345

346 Herbal Pharmacopeia
compliance of the treatment regimens especially compounded by the complex nature of the traditional herbal preparation dosage (Ambwani et al., 2018; Onyeji, 2022). This has also been made
possible by the development of nano- sized herbal drug systems because the physicochemical barriers hampering the effectiveness of herbal remedies are also well addressed by this invention. A
majority of the herbal constituents have been shown to be of low aqueous solubility and high molecular weights and thus cannot easily diffuse across biological membranes. These compounds, when
formulated using nanotechnology, can be delivered in the form of nanoparticles that could easily
cross lipid membranes and therefore augment their bioavailability (Kesarwani & Gupta, 2013;
Azzahra et al., 2020). For instance, ethosomes and transfersomes are suggested to be a better method
of transdermal delivery of herbal drugs, leading to better absorptive ability through the skin and a
better response from the drugs (Chen et al., 2022; Rahman et al., 2020). Moreover, the application
of nanocarriers in the system of herbal drug delivery enable the controlled and prolonged releases of
the drug. This slow release is benecial for the constant release of therapeutic drugs and regular
upkeep of their blood concentration, thereby increasing patient compliance, especially in the context
of compound chronic diseases (Jalali, 2022; Razavi, 2024). It is also possible to control the physicochemical properties of these nanocarriers so that they only release the herbal compounds at the
desired site and time in response to some physiological stimuli such as pH or temperature (Bonifácio
et al., 2013; Ansari et al., 2012). Indeed, nanotechnology is used in the improvement of the bioavailability of the active ingredients, controlled release and reduction of toxicity levels as associated with
herbal medicines. The problem with these compounds is that they have several adverse effects.
However, when herbal extracts are enclosed in nanoparticles, which are biocompatible and biodegradable, several of these issues are mostly likely to be avoided. This is specically the case with
plant extracts as these too may possess powerful biological effects, but are equally likely to cause
toxicity when given in large doses (Darji et al., 2022; Wani et al., 2015). One advantage that is
coupled with NDDS is the potential to give smaller concentrations of the active pharmaceutical
ingredients but to give cure dosages. Furthermore, advances in technology has seen nanotechnology
incorporated into the herbal medicine, which has provided a way through which diseases can be
treated. Because the interaction between nanoparticles and tissues or cells depends on surface chemistry, researchers can modify the surface chemistry of nanoparticles so as to have a higher afnity to
certain tissues or cells, thus enabling pharmacists to deliver herbal drugs to the desired location,
such as tumors or inamed tissues (Marella & Prasad, 2018; Gunasekaran et al., 2014). It also
increases the therapeutic effectiveness and therapeutic window of the herbal medicine while minimizing the occurrence of systemic side effects and related risks to patients, thereby increasing
patients’ safety (Metkari, 2023; Gopi & Amalraj, 2016). The following are some of the real- life
examples of nanotechnology in herbal drug delivery: Route of administration here also plays a signicant role, the common routes being oral, transdermal and intravenous. Every route has its advantages and problems in terms of the improvement of delivery of the herbal products. For instance, oral
delivery systems can be designed to protect herbal compounds from degradation in the gastrointestinal tract, while transdermal systems can facilitate the direct absorption of active ingredients
through the skin (Arsude, 2023). Nanogels, and especially nanoemulsions have demonstrated
improvements in stability and bioavailability of herbal formulations for numerous therapeutic uses
(Alharbi et al., 2021).
16.1.1 AdvAntAges of HerbAl drugs
Herbal formulations are preparations composed of one or more herbs or processed herbs, designed
to provide nutritional, cosmetic, or therapeutic benets for humans or animals. These formulations
are produced through processes such as the extraction, distillation, or fermentation of whole plants,
plant parts, or their derivatives, resulting in products like powders, tinctures, extracts, oils, and juices
(Elkordy et al., 2021).

Targeted Delivery Systems for Herbal Drugs 347
Herbal drugs have gained signicant attention in recent years because of the various advantages
that come with it as a natural product over chemically synthesized drugs. These benets includes
factors like: safety, effectiveness, cost and the prospect for fewer side effects. It is evident that the
usage of herbs has constantly improved time by time due to the fact that these treatments have been
used for thousands of years by the Ayurveda and traditional Chinese medicine practices. The use
of herbal drugs has a number of benets. of which one is that they are safe to use. Some of the
herbal medicines are obtained from natural products, and thus it has been established that they
have been in use for generations. When compared with synthetic drugs, the latter more frequently
have severe side effects and toxicities (Kumari et al., 2021; Murshed et al., 2023; Zhou et al.,
2017). This safety is especially benecial where chronic conditions require long- term use of the
intervention in question. For example, it has been conrmed that the herbal medicine is quite useful in the treatment and control of rheumatoid arthritis and there are fewer side effects compared
to the traditional medicine (Li, et al., 2022; Vyshnevska et al., 2022). Economy is another advantage of herbal drugs that cannot be over- emphasized. In general, the cost of producing herbal medicine and procuring them is cheaper than synthesizing chemical- based medicines hence can reach
many people (Akintelu et al., 2021; Murshed et al., 2023). This affordability is particularly importance in the low- income zones because people may not have adequate healthcare. Also, people that
take herbal medicine do so at their own expense, hence they are less likely to burden the healthcare
system with numerous charges, especially in the case of chronic diseases as they seek medical
attention using these natural products, which are often cheaper than chemically produced drugs
(Murshed et al., 2023; Mohammadi et al., 2020). Another factor that supports the effectiveness of
herbal drugs is versatility of the preparation since they are often composite by nature. Most herbal
medicines may contain several active ingredients which may, in a way, complement each other in
an effort to boost their efcacy. Such mechanism of action of herbal drugs helps them modulate
several pathways in the body, a valuable characteristic in treating complicated diseases such as
cancer and diabetes (Yin et al., 2013; Yang et al., 2018). For instance, studies have suggested that
herbal medicines enhance the body’s ability to ght infections, also enhance the general well- being
of cancer patients even if they use conventional treatments (Yin et al., 2013). In addition, the formulation of herbal drugs can be improved using newer concepts like phytosomes and nanocarriers.
These new and complex drug delivery systems can enhance the dissolution and bioavailability of
herbal ingredients, thereby enhancing therapeutic efcacy as reported by a number of researchers
(Nandhini and Ilango, 2021; Gaikwad et al., 2021; Dongare et al., 2021). When such technologies
are incorporated in the application of these plants, the curative value of the medicinal herbs can be
enhanced, and therefore function as potential substitutes or adjuncts to modern synthetic drugs.
However, the two options come with certain qualities that are linked with the usage of the herbal
drugs; they have therapeutic values; they are also said to be holistic in the treatment. Most natural
remedies for diseases are compounded in such a way that in addition to curing a particular disease,
they help maintain health and harmony in the body. This view is of the whole- person approach
which characterizes traditional systems of medicine and more so Ayurveda, where the focus is not
on treating disease but on managing the affected individual. In addition, awareness regarding
herbal medicines has grown signicantly, creating awareness into formulation to expose new active
ingredients and therapeutic uses. This is because this ongoing research is useful for the conrmation of the effectiveness of these herbal drugs destined for modern medicine and to establish their
safety for use (Mohammadi et al., 2020; Kuruüzüm- Uz et al., 2012; Razavi, 2024). For instance,
researchers have established that a number of phytochemicals possess strong anti- inammatory
and antioxidant characteristics that are useful for medical use (Kuruüzüm- Uz et al., 2012; AboZeid et al., 2021). While appreciating the benets of herbal drugs, one should not close eyes to the
problem attendant with their use. Among the challenges that need to be considered are standardization, quality assurance and control, as well as possible herb–drug interactions (Dragos et al., 2017;
Ogawa- Ochiai & Kawasaki, 2019).

348 Herbal Pharmacopeia
16.1.2 CHAllenges of HerbAl drugs
Around the globe to date, an estimated 422,000 species of plants have so far been identied for
medicinal purposes. Of this total number, some 52,000 (around 12.5%) plant species are currently
being used for different medical purposes. 4160 (nearly 8%) of the medicinally important plants are
kept in the ‘threatened’ category. Many of these plants have not yet been fully explored for their true
biological activities. Only a few of the plants have been identied, well- characterized and listed in
ofcial pharmacopoeias (Pan, 2014).
Therefore, herbal medicines and drugs are not without disadvantages, and hence, they cannot be
applicable to all disease conditions. Although herbal drugs offer a lot of advantages, there is a downside as well, with some serious risks being associated with the consumption of herbal drugs (Studdert,
et al. 1998).
With developments in biomedical sciences, advancements in isolation and characterization techniques, in vivo and in vitro studies, toxicological studies, novel drug delivery mechanisms and
deeper understanding of biological systems, along with the discovery of new therapeutic targets in
bodies, drug discovery overall remains a lengthy, very expensive, laborious, and inefcient process.
Hence, there is still a low rate of new therapeutic drug discovery (Tang, K., 2011).
There are several notable challenges associated with the herbal drugs, including:
a. The regulations of herbal drugs. The US Food and Drug Administration (FDA) has much
more stringent rules for the manufacturers of pharmaceutical drugs than are applied to
herbal manufacturers.
b. Herbal drugs interact and interfere with other drugs and foodstuffs, which may cause seri-
ous, harmful effects (Raynor D. K 2011).
c. The lack of dosage instructions leads to either low dosage or over dosage since people take
herbal medication by self- dosing.
d. Herbal drugs may pose serious allergic reactions. Before using herbal medicines, one must
ensure the allergic test for that herbal drug. Conventional medicines are taken with a prescription, so they pose lower risks of allergy.
e. One major issue associated with herbal formulations is their adulteration with foreign
substances like steroids and heavy metals. This can lead to serious renal problems.
The shelf- life of herbal medicines is another big issue. The herbal medicines are a mixture of different chemical substances. The variety of phytoconstituents may differ in terms of properties such as
shelf- life, pharmacokinetics, and pharmacodynamics. Changes in these properties alter the biological actions of a drug. Currently, available knowledge cannot address these disadvantages of herbal
formulations (Izzo, A. A. 2004).
16.1.3 rise of tArgeted delivery for HerbAl drugs
The targeted drug delivery system is a technique that enables us to deliver the drug to the designated
site of action and has a signicant effect on the medicine’s efcacy. What comes into play here is
the role and the bioavailability at the target site alongside specic herbal drug activity (Dongare
etal., 2021).
Traditional drug delivery strategies (oral, nasal, or transdermal injections as different routes of
administration) display systemic adverse side effects (Hassan and Zhang, 2019). These effects may
include inconsistent drug release, or off- target and non- specic biodistribution, which may disrupt
the overall drug- targeting mechanism. Hence, the development of new drug delivery system facilitates the controlled release of drug payloads at the target site. Novel drug delivery systems can
reduce herbal drug dosing frequency while keeping the drug concentration in the targeted cells,
organs or tissue for a prolonged period (Singh & Sharma, 2023).

Targeted Delivery Systems for Herbal Drugs 349
In the preceding sections, we will dive deeper into different carrier systems and detailed mechanisms involving the drug delivery systems overall, with the specic context of herbal drugs.
16.2 CARRIERS SYSTEMS FOR TARGETED DRUGS
Targeted drug delivery (TDD) is a precise method of delivering drugs directly to specic areas of the
body, thereby reducing side effects and improving treatment effectiveness. TDD uses various carriers, such as polymers, nanoparticles, liposomes, and micelles, to transport drugs to their intended
targets. The drug carrier systems used for the purpose of targeted drug delivery are in fact tiny cargocarrying vehicles that transport drugs/active compounds or herbal compounds to a specic location
in the body. The drug cargo- carrying vehicles are designed in such a way that they support the safe
and controlled release of the drug molecules at the target site. They also avoid unloading the drug
off target (Dunuweera, 2019).
Nanotechnology and nanomedicine are making great contributions to revolutionizing the horizon
of drug delivery. The purpose of these domains of research is to offer better drug targeting as well as
safe and controlled release of the drug compounds. Traditional delivery systems have many shortcomings, which include rapid drug release from cell or target site and low specicity. Nanotechnology
offers a lot of variety in the form of nanocarriers, which provide a very precise and efcient way to
transport drugs to their intended target sites.
Nanocarriers offer a variety of chemistries and combinations. Different polymers (bio- based polymers and inorganic polymers or a mixture of both), nanoparticles (metallic, non- metallic, biological),
and liposomes (phospholipids) may all act as tiny delivery vehicles that enhance drug delivery, targeting, and safe release & effectiveness. By reducing side effects and minimizing adverse effects, nanomedicine offers a promising approach for improving the effective treatment of a number of diseases.
Overall, nanocarriers enhance the cellular update of drug and therapeutic outcomes.
In this section, we will discuss liposomes, polymeric nanoparticles, nanocapsules and nanospheres, polymeric micelles, dendrimers, carbon nanotubes, aptamers, and DNA nanocarriers. We
will discuss the currently used drug carriers as well as explaining the exciting domains of DNA
nanotechnology and functional nucleic acids as potential drug delivery vehicles. These relatively
new elds of science and biomedical research have not yet been explored and herbal drugs are not
making full use of the potential of these elds.
16.2.1 liposome- mediAted drug delivery system
Liposomal drug delivery systems can be considered to be one of the most signicant advancements
in the pharmaceutical sciences, especially in relation to the optimization of the pharmacodynamics
and pharmacokinetic characteristics of different drugs. These systems incorporate liposomes which
are spherical vesicles consisting of a lipid bilayer and are capable of encapsulating both aqueous
soluble and water- insoluble drugs, thereby enhancing their stability, solubility, and pharmacokinetic
properties. The relative size and shape of liposomes can be used to release their contents gradually
and with a low risk of undesirable side effects at loci tissues, organs, and cells where the encased
agents need to act (Gumulec et al., 2014; Smits et al., 2018). An important advantage of liposomal
formulations is that they can improve the solubility and stability of compounds which are poorly soluble in water. For example, doxorubicin encapsulation in liposomal formulations was demonstrated
to increase its therapeutic window through a decreased cardiotoxic effect without compromising the
cancer cell- killing potential (Gumulec et al., 2014; Smits et al., 2018). This entrainment not only
shields the drug from being degraded but also assists the drug in crossing biological membranes,
thereby boosting its bioavailability. This has been done to show that liposomal formulations can
produce a higher plasma level of drugs than the non- encapsulated drugs, which in turn enhance the
therapeutic effects (Yi et al., 2013; Nogueira et al., 2015b). In addition, liposomes can be designed
to have the capabilities of passive or active targeting of tissues or cells. Passive targeting makes use

350 Herbal Pharmacopeia
of what is known as the enhanced permeability and retention (EPR) effect, whereby, liposomes are
allowed to penetrate and adhere to tumor tissues due to the hyperpermeability of their blood vessels
(Shigehiro et al., 2014; Sercombe et al., 2015). Active targeting, however, concerns the alteration of
liposomal surfaces with ligands that can interact with receptors present over the targeted cells, such
as folic acid receptors in cancer cells Nogueira et al., 2015a). It not only increases the accumulation
of the drug at the targeted site but also decreases the side effects at the other sites, further improving
the overall safety of the treatment (Niu et al., 2015). The formulation versatility of liposomal delivery systems is an added bonus to the versatility of the system. Liposomes can incorporate almost
any pharmacologic agents in their core or incorporated in the bilayer, such as small molecules,
peptides, proteins, and nucleic acids for delivery (Akbarzadeh et al., 2013; Schwendener & Schott,
2017). Such exibility also enable a technology that can encapsulate several drugs simultaneously,
which is benecial when the drugs are administered together in the cases of chronic illnesses such as
cancer. For instance, the ability to deliver chemotherapeutic agent and siRNA simultaneously using
liposomes has been found to improve the effectiveness of overall treatment also lower the dosages
of each agents (Niu et al., 2015; Grace, 2014). In addition to its uses in therapy, liposomes have also
been considered as carriers for vaccines. Liposomes have the capability to successfully delivering
antigens and improve the immunogenicity of vaccines. This is well informed by the development of
liposomal adjuvants for the enhancement of immune response to co- administered antigens, which
is a process that is discussed by Schwendener & Schott (2017). Liposomes possessing capacity to
encapsulate both the hydrophilic and the hydrophobic component make them a suitable approach
for developing new vaccine formulations. Although the liposomal drug delivery systems have been
associated with many benets, there are several challenges that need to be overcome for the system
to have higher value in clinical applications. One major concern is the low percentage of encapsulation that is sometimes reported with certain drugs, hence conning the benets of liposome formulations (Skrinda et al., 2021; Sreekanth et al., 2017). There are great disparities in lipid composition,
preparation methods, and drug properties which inuence the efciency of encapsulation and release
kinetics (Teong et al., 2014; Pentak et al., 2011). The continual study is directed towards modifying
these parameters to optimize situations with liposomal systems. In addition, the tendency of liposomal formulations to degrade in the course of storage, and their compatibility during administration,
is of the essence. Liposomes are liable to aggregation, fusion, and leakage out of the sheltered pharmaceutical, and that again will affect its usefulness (Guimarães et al., 2019; Pauli et al., 2019). Other
approaches include the addition of stabilizers or the employment of the microuidic technology for
the improvement of liposomal formulations’ shelf stability (Elsana et al., 2019; Zheng et al., 2022).
More recently, advancements in liposome- mediated drug delivery have centered on bioconjugation strategies. Liposomes, a widely used nanoparticle carrier, have been modied to improve drug
loading, targeting, and overall efcacy. These improvements aim to enhance the delivery of therapeutic agents to various sites of action (Almeida et al., 2020).
Despite all the potential applications of liposomes, the development and application of liposomes
remain a challenge due to their complex production processes. Researches are being carried out with
the aim to overcome these hurdles (Farooque et al., 2021).
16.2.2 polymeriC nAnopArtiCles As drug CArriers
Polymeric nanoparticles rang in size from 1 to 1000 nm. These nanoparticles can be loaded with
either drugs or active compounds. The loaded compounds are either trapped inside or absorbed onto
the surface of the polymeric core (Zielinska, A.,2020). The term ‘nanoparticle’ can be used in the
cases of both nanospheres and nanocapsules. Nanocapsules are made up of an oily core. In this oily
core the drug is dissolved. The core is encircled by a polymeric shell, which controls the release of
the entrapped drug from the core. By contrast, s nanospheres contain a continuous polymeric network. The loaded compound drug may be retained inside the core or adsorbed onto the surface of

Targeted Delivery Systems for Herbal Drugs 351
FIGURE 16.1 a) Liposome Hydrophobic heads towards the outside and hydrophilic tails towards the inner
core, drug molecule in the center. b) Polymeric Nanoparticle, drug molecule in centre, Nanocapsule and
Nanosphere shown containing the drug molecules. c) Phytosome with drug molecules . d) Polymeric Micelle,
drug molecules, Targeting agent in green, moiety sensitive to stimuli, polymeric coat e) Dendrimer, upper
left side without modication of functional groups, positively and negatively charged groups in, hydrophobic
drug and nucleic acid shown. Upper right side, modication with different agents’ amino acid, antibody and
protein. Lower right side, modication with carbon nanotube. Lower left side, modication with PEGylation,
f) Carbon Nanotube carrying different types of cargo, g) Barrel shaped DNA origami, structure made up of
scaffold and staple strands, different cargos can be loaded on to origami, the cargo is injected in mice to deliver
drugs to target site.
nanosphere (see Figure 16.1b). Essential oils have been efciently delivered by polymeric nanoparticles (Lammari N., 2020).
The main characteristics of polymeric NPs, are that they are biocompatible and biodegradable
and that they pose low- toxicity risks (Pinelli F., 2020).
According to a study conducted by Maurya et al. (2019), polymeric NPs can be safely used by
humans. Similarly, polymeric NPs can signicantly improve the bioavailability of the loaded drugs.
They are stable and can encapsulate large amounts of guest molecules. Recent studies on biodegradable and non- biodegradable polymers suggest that both type of polymeric nanocarriers can be used
for oral drug delivery (Maurya A., 2019).
It is worthwhile mentioning here the successful study in which pure curcumin was compared
with curcumin- loaded polymeric NPs. The polymeric formulation provided 5.6-fold higher oral
bioavailability (Chen, Y., 2020).
Polymeric nanoparticles are emerging as a groundbreaking solution to address the complexities of
drug delivery. Key advantages of polymeric nanoparticles include enhanced bioavailability, targeted
delivery, controlled release, and versatility. Applications include cancer therapy, ocular drug delivery,

352 Herbal Pharmacopeia
and nutraceutical delivery. The eld of polymeric nanoparticles is rapidly evolving as scientists continue to explore the potential of these innovative materials. We can expect to see even more exciting
advancements in drug delivery in the years to come (Begines et al., 2020).
Polymeric nanoparticles show promise in cancer treatment. They can deliver drugs directly to
tumors, thereby reducing side effects and improving therapeutic outcomes. These nanoparticles
have potential applications in various cancers: ovarian, colorectal and others, and brain tumors
(Madej et al., 2022).
Nanoparticles can be modied to improve their effectiveness and they are being explored for
various therapeutic applications (Dristant et al., 2023).
16.2.3 miCelles
Polymeric micelles are promising nanocarriers for the delivery of anticancer drugs, offering advantages such as targeted drug delivery, improved biocompatibility, and reduced side effects. (Elumalai
et al., 2024).
Micelles involve self- assembly techniques. Micellar carriers are used in vast nanomedicine applications. They involve techniques, including:
• Interaction with biological substances
• Kinetic stability
• Drug release
These techniques are crucial for understanding drug delivery systems (Ghezzi et al., 2021).
Polymeric micelles are promising nanocarriers for delivering anticancer drugs. They can encapsulate both hydrophilic and hydrophobic drugs and release them in a controlled manner.
Micelles are useful for delivering different anticancer drugs. Considering factors such as methods and computational analysis, micelles are promising nanomaterials that can be used to target
drug delivery (Guzmán Rodríguez et al., 2023. Physically, micelles are uorescent materials that
exhibit enhanced emission when aggregated. They have various applications in bioimaging, drug
delivery, and therapy (Liu et al., 2023). Micelles are useful nanostructures that can be used in the
targeting of cancer treatment. They can deliver both drugs and genes, enhancing cancer therapy.
Various types of smart micelles, including pH- sensitive and multi- responsive micelles, can be used
for targeted drug delivery. The combination of micelles and nanostructures can further enhance
their potential in cancer treatment. Studies have shown that micelles are highly compatible and safe
(Gao et al., 2024).
16.2.4 dendrimers
Dendrimers are highly branched polymers. They were rst developed in 1978 by Buhleier et al.,
when they were named cascade polymers. These cascade polymers laid the foundation of polypropylene imine dendrimers, which were developed in the 1990s. The name dendrimer is derived from
the Greek words ‘dendron,’ which means tree or branch, and ‘meros.’ Which means part.
At molecular level, dendritic branching gives a semiglobular or globular structure to the dendrimer. The surface contains a small molecular volume with a high density of functionalities. The
structure of a typical dendrimer comprises three different structural parts (see Figure 16.1e):
a. Core at the center (either a single atom or an atomic group), having at least two identical
chemical functions.
b. Building blocks providing numerous interior layers made up of repeating units. It provides
exible space to different guest molecules.

Targeted Delivery Systems for Herbal Drugs 353
c. Multiple functional groups at the peripheries of macromolecule exteriorly. It plays the
major key role in the overall properties of the dendrimer. This part denes the macroscopic
properties of the dendrimer.
This structural assembly and overall 3D structural complex of dendrimers confers unique properties, such as a globular shape at the nanoscale, functional groups at the peripheries, hydrophilic and
hydrophobic cavities in the interior, and low polydispersity.
The globular structures, and the diameter of less than 10 nm, is very similar to the molecular size
of biomolecules and proteins. Hence dendrimers act as biomimics. Overall, dendrimers provide
structural complexities along with opportunities for accommodating and carrying drug molecules,
targeting moieties like antibodies, and solubilizing groups like PEG on the surface (see Figure 16.1e).
Dendrimers have demonstrated their potential as nanocarriers for different types of drugs like
antimicrobial, anticancer, and anti- inammatory drugs.
16.2.5 CArbon nAnotubes And fullerenes
Carbon nanotubes (which are abbreviated as CNTs) have a cylindrical shape. The sheets of carbons
are, in fact, hexagonally ordered carbon atoms. This structural feature gives the nanotubes a diameter of few nanometers and length ranges of up to a few micrometers. Carbon nanotubes may be
either single- walled (SWCNTs) or multi- walled (MWCNTs) (Zare, H., 2021).
Structurally, carbon nanotubes are hollow nanobers, and this structural characteristic makes
them attractive candidates for the delivery of drugs and diagnostic agents. Similarly, other properties
of CNTs including high biocompatibility, enhanced conductivity, high surface- to- volume ratios,
ease of functionalization, strength, and optical properties (Serpell, C. J., 2016) make them novel
drug delivery carriers (see Figure 16.1f).
The biggest concerns associated with the use of CNTs in the eld of biomedical sciences have
centered around two main issues, biodegradability and toxicity.
In addition to these negative features of carbon nanotubes, a lot of research is still being carried
out in this domain of science. Among the notable applications of CNTs are their functions in the
elds of biosensors, drug delivery systems, bioimaging, vaccine delivery, gene delivery, gene therapy and diagnostic applications (Mahor, A., 2021).
Fullerene is an allotrope of carbon and usually described as a molecular form of carbon. In fullerene, carbon atoms (n > 20) are clustered on a spherical surface. The most studied of these forms is
fullerene C60. The water solubility of fullerenes can be improved through the grafting and functionalization of different chemical groups. In this way new drugs can be obtained. Different studies have
been reported in which functionalized fullerenes have been used for therapeutic and diagnostics
applications. Functionalized derivatives of fullerenes are mainly focused in the areas of quenching
reactive oxygen species (ROS), drug delivery and bioimaging (Debnath, S. K., 2021).
But keeping the real- life concern in biomedical sciences, the eld of CNT still has a long way to go
due to the inaccurate and relatively low number of toxicity studies (Nimushakavi, S., 2021).
Nevertheless, it is hoped that more research in the coming times will make CNTs workable. In this
respect, herbal medicines can benet from this domain of nanotechnology for drug delivery purposes.
16.2.6 pHytosomes
Phytosomes are lipid- based complexes of herbal drug/plant extract with phospholipids. It’s a relatively new technology, being invented by Indena in 1989. Another name for phytosomes is phytophospholipid complexes. The name itself is self- explanatory, since it describes the interaction
between herbal drug/phyto compounds and the hydrophilic parts of phospholipids through hydrogen
bonds (see Figure 16.1c).
Соседние файлы в папке Библиотека им академика М.И. Перельмана
